High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine

, , &
Journal of Law, Medicine and Ethics 50 (2):380-384 (2022)
  Copy   BIBTEX

Abstract

Gene therapies to treat sickle cell disease are in development and are expected to have high costs. The large eligible population size — by far, the largest for a gene therapy — poses daunting budget challenges and threatens to exacerbate health disparities for Black patients, who make up the vast majority of American sickle cell patients.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2022.66

Other Versions

No versions found

Links

PhilArchive

    This entry is not archived by us. If you are the author and have permission from the publisher, we recommend that you archive it. Many publishers automatically grant permission to authors to archive pre-prints. By uploading a copy of your work, you will enable us to better index it, making it easier to find.

    Upload a copy of this work     Papers currently archived: 106,169

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Medicine, Culture, and Sickle Cell Disease.Troy Duster - 2002 - Hastings Center Report 32 (4):46-47.
Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine.Deanne Dunbar Dolan, Mildred K. Cho & Sandra Soo-Jin Lee - 2024 - AJOB Empirical Bioethics 15 (2):87-92.
Changing the Shape of Sickle Cell Disease Treatment: A Hermeneutic Study of a Case that Changed a Family and a Medical Practice.Nancy J. Moules, Catherine M. Laing & Gregory Guilcher - 2017 - Journal of Applied Hermeneutics 2017 (1).
Affordable pricing of CRISPR treatments is a pressing ethical imperative.Jon Rueda, Íñigo De Miguel Beriain & Lluis Montoliu - 2024 - CRISPR Journal.
Red Crescents: Race, Genetics, and Sickle Cell Disease in the Middle East.Elise K. Burton - 2019 - Isis 110 (2):250-269.
Improving the justice‐based argument for conducting human gene editing research to cure sickle cell disease.Berman Chan - 2019 - Bioethics 34 (2):200-202.
Germline Gene Editing for Sickle Cell Disease.Akshay Sharma, Nickhill Bhakta & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (8):46-49.
Estimation of C-Reactive Protein, Immunoglobulin’s and Complements in SCD Patients.Maha Khalaf Al-Mishry, Nadhim K. Mahdi & Sadeq K. Ali AlSalait - 2018 - International Journal of Academic Health and Medical Research (IJAHMR) 2 (6):1-4.
Disrespectful Care in the Treatment of Sickle Cell Disease Requires More Than Ethics Consultation.Carlton Haywood - 2013 - American Journal of Bioethics 13 (4):12 - 14.
Not Your Typical Frequent Flyer: Overcoming Mythology in Caring for Sickle Cell Disease Patients.Dowin H. Boatright & Jean Abbott - 2013 - American Journal of Bioethics 13 (4):18 - 20.

Analytics

Added to PP
2022-07-29

Downloads
24 (#1,005,806)

6 months
2 (#1,359,420)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Add more citations

References found in this work

No references found.

Add more references